Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-14
2011-06-14
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S308000, C530S324000, C530S344000, C435S366000, C424S009100
Reexamination Certificate
active
07960344
ABSTRACT:
The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
REFERENCES:
patent: 4016100 (1977-04-01), Suzuki et al.
patent: 4311712 (1982-01-01), Evans et al.
patent: 4370349 (1983-01-01), Evans et al.
patent: 4372949 (1983-02-01), Kodama et al.
patent: 4452747 (1984-06-01), Gersonde et al.
patent: 4529561 (1985-07-01), Hunt et al.
patent: 4725442 (1988-02-01), Haynes
patent: 4737323 (1988-04-01), Martin et al.
patent: 4921706 (1990-05-01), Roberts et al.
patent: 4927637 (1990-05-01), Morano et al.
patent: 4944948 (1990-07-01), Uster et al.
patent: 5008050 (1991-04-01), Cullis et al.
patent: 5009956 (1991-04-01), Baumann
patent: 5789379 (1998-08-01), Drucker et al.
patent: 5834428 (1998-11-01), Drucker
patent: 5952301 (1999-09-01), Drucker
patent: 5990077 (1999-11-01), Drucker
patent: 6297214 (2001-10-01), Drucker et al.
patent: 6586399 (2003-07-01), Drucker
patent: 7176182 (2007-02-01), Drucker
patent: 7642241 (2010-01-01), Drucker
patent: 2006/0105954 (2006-05-01), Drucker
patent: 0612531 (1994-08-01), None
patent: WO 9632414 (1996-10-01), None
patent: WO 9739031 (1997-10-01), None
patent: WO 9825644 (1998-06-01), None
patent: WO 9958144 (1999-11-01), None
Amendment filed in U.S. Appl. No. 09/692,238, filed May 17, 2001.
Barragan, et al., “Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats”, Am. J. Physiology, 1994, vol. 266, No. 3, part 1, E459-66.
Brubaker, et al., “Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides”, Endocrinology, 1991, vol. 128, No. 6, 3175-3182.
Buhl, et al., “Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine”, J. of Biological Chemistry, 1998, vol. 263, No. 18, 8621-8624.
Calvo, et al., “Structural characterization by affinity cross-linking of glucagon-like peptide-1(7-36) amide receptor in rat brain”, J. Neurochem., 1995, vol. 64, No. 1, 299-306.
Chasin, et al., “Biodegradable polymers as drug delivery stems”, Drugs and the Pharmaceutical Sciences, 1990, vol. 45.
Cheeseman, et al., “The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal basolaterial membrane hexose transport”, The American Physiological Society, 1996, Abstracts 3:0071G.
Dayhoff, Atlas of Protein Sequence and Structure, vol. 5, p. 96, (1972).
Drucker, et al., “Intestinal response to growth factors administered alone or in combination with human GLY2 glucagon-like peptide 2”, Am. J. of Physiology: Gastrointestinal and Liver Physiology, vol. 273, No. 6, part 1, 1997, G1252-G1262.
Drucker, et al., Proc. Natl. Acad. Sci. USA, vol. 93, 1996, 7911-7916.
Drucker, et al., “Glucagon and the glucagon-like peptides”, Pancreas, 1990, vol. 5, No. 4, 484-488.
Ehrlich, et al., “Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors”, American Journal of Physiology, 1994, E662-E671.
George, et al., “Molecular forms of glucagon-like peptides in man”, FEBS Letters, 1985, vol. 192, No. 2, 275-278.
Hoosein, et al., “Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase”, FEBS Letters, 1984, vol. 178, No. 1, 83-86.
Irwin, et al., “Trout and chicken proglucagon: alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2”, Molecular Endocrinology, 1995, vol. 9, 267-277.
Litvak, et al., “Glucagon-like peptide is a potent growth factor for small intestine and colon”, J. of Gastrointestinal Surgery, 146-150, (1998).
Litvak, et al., “Glucagon-like peptide 2: a potent intestinal growth factor”, Gastroenterology, 112:A1455, (1997).
Mosjov, et al., “Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translation processing”, J. of Biological Chemistry, 1986, vol. 261, No. 25, 11880-11889.
Notice of Allowance with Examiner Amendments issued in U.S. Appl. No. 09/692,238 dated Feb. 3, 2005.
Notice of Allowance issued in U.S. Appl. No. 10/419,150 dated Sep. 20, 2006.
Office Action issued in U.S. Appl. No. 09/149,831 dated Mar. 31, 1999.
Office Action (final) issued in U.S. Appl. No. 09/149,831 dated Dec. 28, 1999.
Office Action issued in U.S. Appl. No. 09/149,831 dated Sep. 25, 2000.
Office Action issued in U.S. Appl. No. 09/692,238 dated Dec. 17, 2001.
Office Action (final) issued in U.S. Appl. No. 09/692,238 dated Sep. 19, 2002.
Office Action issued in U.S. Appl. No. 10/419,150 dated Jun. 17, 2005.
Office Action (final) issued in U.S. Appl. No. 10/419,150 dated Mar. 2, 2006.
Office Action issued in U.S. Appl. No. 11/654,668 dated Oct. 31, 2007.
Office Action (final) issued in U.S. Appl. No. 11/654,668 dated Jul. 28, 2008.
Orskov, et al., “Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas”, Endocrinology, 1986, vol. 119, No. 4, 1467-1475.
Orskov, et al., “Pancreatic and intestinal processing of proglucagon in man”, Diabetologia, 1987, vol. 30, 874-881.
Orskov, et al., “Carboxypeptidase-B-like processing of the C-24, terminus of glucagon-like peptide-2 in pig and human small intestine”, FEBS Letters, 1989, vol. 247, No. 2, 193-196.
Orskov, et al., “Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2”, Scand. J. Clin. Lab. Invest., 1987, vol. 47, No. 2, 165-174.
Request for Continued Prosecution filed in U.S. Appl. No. 09/149,831, filed Jun. 28, 2000.
Response to Office Action filed in U.S. Appl. No. 09/149,831, filed Sep. 28, 1999.
Response to Office Action filed in U.S. Appl. No. 09/692,238, filed Jun. 17, 2002.
Response to Office Action filed in U.S. Appl. No. 09/692,238, filed Nov. 26, 2002.
Response to Office Action filed in U.S. Appl. No. 10/419,150, filed Dec. 19, 2005.
Response to Office Action filed in U.S. Appl. No. 10/419,150, filed Sep. 5, 2006.
Response to Office Action filed in U.S. Appl. No. 11/654,668, filed Apr. 29, 2008.
Response to Restriction Requirement filed in U.S. Appl. No. 09/692,238, filed Nov. 5, 2001.
Response to Restriction Requirement filed in U.S. Appl. No. 11/654,668, filed Sep. 25, 2007.
Restriction Requirement issued in U.S. Appl. No. 09/692,238 dated Jun. 4, 2001.
Tsai, et al., “Intestinal growth-promoting properties of glucagon-like peptide-2 in mice”, Am. J. of Physiology: Endocrinology and Metabolism 36, vol. 273, No. 1, 1997, E77-E84.
1149336 Ontario Inc.
Kam Chih-Min
Stoel Rives LLP
LandOfFree
Methods of enhancing functioning of the large intestine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of enhancing functioning of the large intestine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing functioning of the large intestine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2653936